Regeneron UK

Alirocumab (PRALUENT) is a monoclonal antibody developed by Regeneron UK Limited for the treatment of dyslipidemia, a disorder of abnormal lipid levels in the blood. The drug is administered via subcutaneous injection and belongs to the cardiovascular therapeutic class. Alirocumab has completed clinical development and achieved regulatory approval across major markets including the United States, European Union, and Japan. The program is sponsored by Regeneron Pharmaceuticals in the US market, with marketing authorization in the EU held by Sanofi Winthrop Industrie. The latest documented milestone dates to May 2018. Alirocumab competes in a crowded dyslipidemia market alongside other approved therapies including REPATHA (Amgen), LEQVIO (Novartis), and multiple other lipid-modifying agents. The drug's mechanism of action and specific molecular target have not been disclosed in available documentation, though its therapeutic class designation (C10) indicates cardiovascular system activity. Regulatory status varies by geography: approved in the US (BLA125559), EU (EMEA/H/C/003882, authorized 17 October 2025), and Japan (July 2016), while clinical trials continue in China (NCT02715726).

Dyslipidemia represents a significant unmet medical need, as abnormal lipid profiles are major risk factors for cardiovascular disease, which remains a leading cause of morbidity and mortality globally. The dyslipidemia treatment market is substantial and growing, driven by aging populations, increasing prevalence of metabolic disorders, and heightened cardiovascular risk awareness. Alirocumab's approval across multiple major regulatory jurisdictions positions it as an established therapeutic option within a competitive landscape that includes both monoclonal antibodies and small-molecule lipid-modifying agents. The patient population for dyslipidemia is large and heterogeneous, encompassing individuals with primary hypercholesterolemia, familial hypercholesterolemia, and mixed dyslipidemia. Commercial significance is underscored by the presence of multiple approved competitors and ongoing clinical development in emerging markets such as China, indicating sustained market demand. The injectable route of administration and cardiovascular indication align with established treatment paradigms for high-risk lipid management, particularly in patients requiring intensive LDL-cholesterol reduction.

Drug Class: Monoclonal antibody targeting lipid metabolism.

Modality: The facts indicate a small-molecule classification; however, alirocumab is clinically recognized as a monoclonal antibody, suggesting a potential data discrepancy.

Route of Administration: Subcutaneous injection.

Therapeutic Class: Cardiovascular system (C10) — lipid-modifying agent.

Mechanism of Action: Not disclosed in available documentation.

Molecular Target: Not disclosed in available documentation.

Brand Name: PRALUENT.

International Nonproprietary Name (INN): Alirocumab.

Related Therapies: REPATHA (Amgen), LEQVIO (Novartis), EVKEEZA (Ultragenyx), KYNAMRO, and other approved dyslipidemia agents.

First Approval: Japan, July 2016; subsequently approved in the US and EU.

Patent Status: Not yet disclosed.

United States (FDA): Approved; Biologics License Application (BLA) number BLA125559 held by Regeneron Pharmaceuticals.

European Union (EMA): Approved; European Medicines Agency authorization EMEA/H/C/003882 granted 17 October 2025, with marketing authorization holder Sanofi Winthrop Industrie.

Japan (PMDA): Approved; authorization granted July 2016.

China (NMPA): Clinical trials ongoing; NCT02715726 registered on ClinicalTrials.gov, indicating investigational status in China.

Approval History: Chronologically, Japan approval (July 2016) preceded US and EU authorizations. The EU authorization date of 17 October 2025 represents the most recent documented regulatory action.

Marketing Authorization Holders: Regeneron Pharmaceuticals (US); Sanofi Winthrop Industrie (EU).

Strategic Positioning: Alirocumab's approval across three major regulatory jurisdictions (US, EU, Japan) with ongoing clinical development in China demonstrates Regeneron's commitment to establishing global market presence in dyslipidemia. The partnership with Sanofi for EU marketing authorization reflects a common co-commercialization strategy in the cardiovascular space.

Competitive Implications: The crowded competitive landscape necessitates differentiation through clinical efficacy, safety profile, dosing convenience, and patient access programs. Alirocumab's established regulatory status provides competitive advantage over investigational agents, though newer therapies such as LEQVIO may offer alternative mechanisms or improved convenience.

Market Catalysts: Potential future catalysts include label expansions to additional dyslipidemia subtypes, combination therapy approvals, real-world effectiveness data, and market penetration in China upon regulatory approval. Pricing and reimbursement decisions across geographies will significantly influence commercial trajectory.

Data Gaps: Mechanism of action, molecular target, patent expiration dates, peak sales projections, and detailed clinical trial results remain not yet disclosed, limiting comprehensive competitive assessment.